Efficacy and tolerability of perindopril in the treatment of essential hypertension in postmenopausal women;Skuteczność i tolerancja perindoprilu w leczeniu pierwotnego nadciśnienia tȩtniczego u kobiet po menopauzie

Nadcisnienie Tetnicze

Volumn 8, Issue 4, 2004, Pages 263-271

  Kłoś, Jadwiga ^a,e   Suchecka Rachoń, Krystyna ^b,e   Cybulska, Katarzyna ^c,e   Wilkins, Arleta ^d  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b Akademia Medyczna   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d Servier Polska   (Poland)

^e Szpital Grochowski ^*  (Poland)

Author keywords

Angiotensin converting enzyme inhibitors; Hypertension in women; Menopause; Perindopril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; PERINDOPRIL;

ADULT; ARTICLE; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; POSTMENOPAUSE; SMOKING; VERTIGO;

EID: 7044227575     PISSN: 14285851     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mosca L., Manson J.E., Sutherland S.E., Langer R.D., Manolio T., Barrett-Connor E. Cardiovascular disease in women. A statement for Healthcare Professionals From AHA. Circulation 1997; 96: 2468-2482.
2. The Sixth Report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 6). Arch. Intern. Med. 1997; 157: 2413-2446 (tłumaczenie i przedruk: Med. Prakt. 1998; 2: 11-31 i 3: 11-33, Nadciśnienie Tȩtnicze 1998; 2: 54-113).
3. The Sixth Report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 6). Arch. Intern. Med. 1997; 157: 2413-2446 (tłumaczenie i przedruk: Med. Prakt. 1998; 2: 11-31 i 3: 11-33, Nadciśnienie Tȩtnicze 1998; 2: 54-113).
4. The Sixth Report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 6). Arch. Intern. Med. 1997; 157: 2413-2446 (tłumaczenie i przedruk: Med. Prakt. 1998; 2: 11-31 i 3: 11-33, Nadciśnienie Tȩtnicze 1998; 2: 54-113).
5. The Sixth Report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 6). Arch. Intern. Med. 1997; 157: 2413-2446 (tłumaczenie i przedruk: Med. Prakt. 1998; 2: 11-31 i 3: 11-33, Nadciśnienie Tȩtnicze 1998; 2: 54-113).
6. Staessen J. A., Bieniaszewski L., Brosens J. i wsp.: The epidemiology of menopause and associated cardiovascular disease. W: Stimpel M., Zanchetti A. (red.). Hypertension after Menopause. Verlag Walter de Gruyter & Co., Berlin, New York 1997: 21-30.
7. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). Hypertension 2003; 42: 1206-1252.
8. Chambers T. J., Stimpel M., Hatton R.: Role of the renin-angiotensin system in the regulation of bone resorption. W: Stimpel M., Zanchetti A. (red.). Hypertension after Menopause. Verlag Walter de Gruyter & Co., Berlin, New York 1997: 77-84.
9. Antony I., Lerebours G., Nitenberg A. Angiotensin converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996; 94: 3115-3122.
10. London G. M., Courivaux J-M., Stimpel M. i wsp.: Arterial stiffness and extracellular matrix in ovariectomized female spontaneously hypertensive rats. W: Stimpel M., Zanchetti A. (red.). Hypertension after Menopause. Verlag Walter de Gruyter & Co., Berlin, New York 1997: 113-123.
11. Fischer G.M., Swain M.L. Effects of estradiol and progesterone on increased synthesis of collagen in atherosclerotic rabbit aortas. Atherosclerosis 1984; 54: 177-185.
12. Lever A.F., Hole D.J., Gillis C.R., Do inhibitors of angiotensin-I- converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-184.
13. Wassertheil-Smoller S., Anderson G., Psaty B.M. i wsp. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension 2000; 36: 780-789.
14. Zdrojewski T., Szpakowski P., Bandosz P., Pajak A., Wiecek A., Krupa-Wojciechowska B., Wyrzykowski B. Arterial hypertension in Poland in 2002. J. Hum. Hypertens. 2004; 18(8): 557-562.
15. Ghiadoni L., Magagna A., Versari D. i wsp. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-1286.
16. Zhuo J.L., Mendelsohn F.A., Ohishi M. Perindopril alters vascular angiotensin converting enzyme, AT1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39: 634-638.
17. Antony I., Chemla D., Lerebours G., Nitenberg A. Restoration of flow-dependent coronary dilation by ACE inhibition improves papaverine-induced maximal coronary blood flow in hypertensive patients: demonstration that large epicardial coronary arteries are more than conductance vessels. J. Cardiovasc. Pharmacol. 2000; 36(5): 570-576.
18. Schwartzkopff B., Brehm M., Mundhenke M., Strauer B.E. Repair of coronary arterioles after treatment with perindopiril in hypertensive heart disease. Hypertension 2000; 36: 220-225.
19. Thybo N.K., Stephens N., Cooper A. i wsp. Effect of antihypertensive treatment on small arteries of patients with previously untreated hypertension. Hypertension 1995; 25: 474-481.
20. Asmar R., Topouchian J., Pannier B. i wsp. Pulse wave velocity as endpoint in large scale interventional trial. The COMPLIOR study. J. Hypertens. 2001; 19: 813-818.
21. Matsumoto K., Morishita R., Moriguchi A. i wsp. Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model. Hypertension 2001; 37: 270-274.
22. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 patients with prior stroke or transient ischaemic attack. The Lancet 2001; 358: 1033-1041.
23. PROGRESS Collaborative Group. Effect of a perindopril-based blood-pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur. Heart J. 2003; 24: 475-484.
24. The EUROPA study. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double blind, placebo controlled, multicentre trial. The Lancet 2003; 362: 782-788.
25. White H.D. Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors? Commentary. The Lancet 2003; 362: 755-757.
26. Brichard S.M., Santoni J.Ph., Thomas J.R., Van De Voorde K., Ketelslegers J.M., Lambert A.E. Long term reduction of microalbuminuria after 1 year of angiotensin converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients. Diab. Metab. 1989; 16: 30-36.
27. Fogari R., Zoppi A., Lazzari P. i wsp. Ace inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J. Cardiovascular. Pharmacol. 1998; 32: 616-620.
28. Brown N.J., Abbas A., Byrne D., Schoenhard J.A., Vaughan D.E. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation 2002; 105: 304-309.
29. Fressinaud P., Berrut G., Gallois H. Antihypertensive action, clinical and biological acceptability of perindopril: main results in 23 460 patients with mild to moderate hypertension treated for 6 months in general practice. Ann. Cardiol. Angeiol. 1993; 42: 1-9
30. Brown C.L., Backhouse C.I., Grippat J.C., Santoni J.P. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur. J. Clin. Pharmacol. 1990; 39: 327-332.